Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P1TZ
|
|||
| Former ID |
DIB010960
|
|||
| Drug Name |
MLN-977
|
|||
| Synonyms |
CHEMBL73148; CMI977; LDP-977; SCHEMBL16932371; LDP 977; CMI 977; HY-U00260; BDBM50144621; CS-7474; 175212-04-1; UNII-VNR0T3Q498 component YANONWCPCKIWEC-CABCVRRESA-N; N-(4-{(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydrofuran-2-yl}but-3-ynyl)-N-hydroxyurea; Urea, N-(4-((2S,5S)-5-((4-fluorophenoxy)methyl)tetrahydro-2-furanyl)-3-butyn-1-yl)-N-hydroxy-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 2 | [1] | |
| Company |
PharmaEngine
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H19FN2O4
|
|||
| Canonical SMILES |
C1CC(OC1COC2=CC=C(C=C2)F)C#CCCN(C(=O)N)O
|
|||
| InChI |
1S/C16H19FN2O4/c17-12-4-6-13(7-5-12)22-11-15-9-8-14(23-15)3-1-2-10-19(21)16(18)20/h4-7,14-15,21H,2,8-11H2,(H2,18,20)/t14-,15+/m1/s1
|
|||
| InChIKey |
YANONWCPCKIWEC-CABCVRRESA-N
|
|||
| CAS Number |
CAS 175212-04-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [2] |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
| Resolvin D biosynthesis | ||||
| Leukotriene biosynthesis | ||||
| Lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | ||||
| Aspirin triggered resolvin E biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Ovarian steroidogenesis | ||||
| Toxoplasmosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Arachidonic acid metabolism | ||||
| Eicosanoid Synthesis | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007577) | |||
| REF 2 | Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked. Cancers (Basel) 2014 September; 6(3): 1500-1521. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.